AI-CVD vs Eko Low Ejection Fraction Tool (ELEFT)

AI-CVD offers superior usability by performing opportunistic screening on existing CT scans, requiring no additional imaging, radiation, contrast, or workflow disruption. This seamless integration into current radiology workflows minimizes impact on both patients and clinicians. In contrast, ELEFT, while quick, requires the use of a specific Eko digital stethoscope during a physical exam.

AI-CVD provides broader clinical value by performing 11 different opportunistic health screening assessments for cardiovascular and multisystem diseases from existing CT scans, including coronary artery calcium scoring, cardiac chamber volumetry, and bone mineral density analysis. This comprehensive approach allows for the early detection of a wider range of hidden health risks. ELEFT, while valuable for early detection of low ejection fraction, is more narrowly focused on a single indicator of heart failure.

While both tools require direct contact for pricing, Eko's ELEFT, as part of the SENSORA platform, has a clear and established reimbursement pathway with a proposed CMS payment rate of $128.90 per use, effective July 2025. This transparency regarding potential reimbursement provides a more tangible understanding of its financial value and facilitates adoption for healthcare systems. AI-CVD lacks similar public information regarding reimbursement or pricing models.

Eko's ELEFT demonstrates stronger enterprise readiness with explicit statements of HIPAA compliance and Business Associate Agreements (BAA), along with being part of the SENSORAu2122 enterprise platform. Eko also provides a dedicated enterprise help center with defined service level agreements (SLAs) for support. While AI-CVD is FDA-cleared and cloud-deployed, its compliance statements are less explicit, requiring direct vendor contact.

AI-CVD demonstrates a higher degree of innovation by transforming existing CT scans into a comprehensive opportunistic screening platform for 11 different cardiovascular and multisystem diseases. This approach maximizes the value of already acquired imaging data without requiring additional procedures or workflow disruption, representing a significant paradigm shift in preventive medicine. ELEFT is innovative in bringing AI to the point of care via a smart stethoscope, but AI-CVD's broad data utilization from existing resources is arguably more groundbreaking.

Eko's ELEFT, as part of the SENSORA platform, offers comprehensive support and documentation, including a dedicated enterprise help center, user manuals, and an enterprise support desk with defined service level agreements (SLAs) and operating hours. This provides clear resources and channels for assistance. No comparable public information regarding support and documentation is available for AI-CVD.